Synopsis of recent research by authors named "Xiangye Ou"
Xiangye Ou's research primarily focuses on innovative treatment strategies for patients with hepatocellular carcinoma (HCC), particularly those with advanced and unresectable forms, emphasizing combination therapies like lenvatinib, anti-PD-1 antibodies, and transcatheter arterial chemoembolization (TACE).
Recent studies indicate that combining these approaches can lead to improved outcomes, such as increased rates of tumor response and successful conversion to surgical resection in initially unresectable cases.
The development of prognostic scoring models, such as the TAE score, aims to better predict patient outcomes and personalize treatment strategies for HCC patients undergoing combination therapies.